LumaCina today announced the appointment of Mark Crotty as Interim Chief Executive Officer, effective immediately. Crotty will guide the company during its next phase of growth, leveraging his experience in building high-performance organizations and steering complex business transformations.
Crotty brings deep leadership expertise from across the healthcare and life sciences sectors, with a track record of strengthening operational resilience and delivering results through periods of change. His appointment comes at a pivotal time as LumaCina scales its sterile injectables platform and expands its presence across Australia and global markets.
“LumaCina is at an inflection point – with a strong foundation in manufacturing and a growing product pipeline, the company has the opportunity to redefine access to essential medicines,” said Mark Crotty, Interim CEO, LumaCina. “I look forward to working with the team to accelerate execution, deepen our partnerships, and prepare the business for sustained long-term growth.”
During his tenure, Crotty will focus on strengthening supply reliability, driving integration across LumaCina’s commercial and regulatory operations, and advancing the pipeline of value-added sterile injectables. The company is undertaking a search for a permanent CEO but emphasized that Crotty’s leadership will ensure continuity and momentum.
The appointment highlights LumaCina’s commitment to disciplined growth and its focus on ensuring patients, providers, and partners continue to receive reliable access to critical medicines.
